Details

Autor(en) / Beteiligte

• Araújo, Camila Freire
• Oliveira, Iara Barreto Neves
• Silva, Muriel Vilela Teodoro
• Pereira, Ledice Inácia de Araújo
• Pinto, Sebastião Alves
• Silveira, Murilo Barros
• Dorta, Miriam Leandro
• Fonseca, Simone Gonçalves
• Gomes, Rodrigo Saar
• Ribeiro-Dias, Fátima

Titel

New world Leishmania spp. infection in people living with HIV: Concerns about relapses and secondary prophylaxis

Ist Teil von

• Acta tropica, 2021-12, Vol.224, p.106146-106146, Article 106146

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •-Cutaneous leishmaniasis was the main clinical form in patients with HIV/ATL.•-Rates of relapses after treatment were similar in HIV/ATL and HIV/VL patients.•-Counts of T lymphocytes were not different in relapsing or non-relapsing patients.•-Regular use of HAART and viral load were not associated with relapse.•-Secondary prophylaxis did not prevent relapse in all patients with HIV/VL. Coinfection with the human immunodeficiency virus (HIV) and Leishmania impairs immune responses, increases treatment failure and relapse rates in patients with American tegumentary leishmaniasis (ATL), as well as visceral leishmaniasis (VL). There is insufficient data on the treatment, relapse, and secondary prophylaxis in patients coinfected with HIV/Leishmania in Brazil. This study investigated patients with HIV/ATL and HIV/VL to describe the outcome of leishmaniasis in patients assisted at a referral hospital of Brazilian midwestern region. Patients with HIV/ATL (n = 21) mainly presented cutaneous diseases (76.2%) with an overall relapse rate of 28.57% after treatment, whereas HIV/VL (n = 28) patients accounted for 17.5% of the cases. The counts of CD4+ T cells and CD8+ T cells and the CD4+/CD8+ cell ratios at diagnosis or relapses were not significantly different between relapsing and non-relapsing patients. Patients with HIV/ATL or HIV/VL showed high levels of activation markers in CD4+ and CD8+ T cells. The regular use of highly active antiretroviral therapy (HAART) and viral load at the time of diagnosis did not influence the relapse rates. Relapses occurred in 36.4% (4/11) of the patients with HIV/VL receiving secondary prophylaxis and in 5.9% (1/17) of the patients who did not receive secondary prophylaxis (p = 0.06). These data are relevant for the therapeutic management of the patients coinfected with HIV/Leishmania.